Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2009

01-06-2009 | Original Paper

Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer

Authors: Tibor Szarvas, Tobias Jäger, Falk Droste, Markus Becker, Ilona Kovalszky, Imre Romics, Süleyman Ergün, Herbert Rübben

Published in: Pathology & Oncology Research | Issue 2/2009

Login to get access

Abstract

Angiogenesis plays a critical role in tumor growth. VEGF, angiopoietins (Ang-1, Ang-2) and their tyrosine kinase receptor Tie2 are major regulators of angiogenesis. The aim of this study was to evaluate the prognostic value of the serum levels of these factors in bladder cancer. We analyzed the serum samples of 117 bladder cancer patients and 64 healthy volunteers by enzyme linked immunosorbent assay (ELISA) for Ang-1, Ang-2, VEGF and the extracellular domain of Tie2. The statistical evaluation of the obtained data was performed via Kaplan–Meier log-rank test, univariate Cox analyses as well as Cox proportional hazards regression model. Serum Ang-1 levels of bladder cancer patients were significantly higher (p < 0.001), while soluble Ang-2 and Tie2 levels were significantly lower (p = 0.016 and p = 0.001 respectively) in patients than those in controls. Cox univariate analysis revealed high sTie2 serum level as a risk factor for metastasis and as a borderline significant risk factor for disease related death (p = 0.022 and p = 0.081 respectively). These correlations were independent from tumor stage and grade in a Cox multivariate model (p = 0.016 and p = 0.069). These data indicate that the serum levels of analyzed angiogenic factors do change characteristically in bladder cancer. The soluble extracellular serum level of Tie2 may provide a stage and grade independent diagnostic tool to select a high risk group of bladder cancer patients.
Literature
1.
Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesisand metastasis correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMed
2.
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161–1169CrossRefPubMed
3.
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC (1999) Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79:213–223PubMed
4.
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60CrossRefPubMed
5.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMed
6.
Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor flt-1 in squamous cell lung cancer. Int J Cancer 74:64–68CrossRefPubMed
7.
Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S (1997) Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer 79:206–213CrossRefPubMed
8.
Maeda K, Chung Y, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y et al (1995) Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 13:477–481PubMed
9.
Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F (1997) Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 3:2451–2458PubMed
10.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2006) Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 16:405–411CrossRefPubMed
11.
Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H (2001) Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 166:1275–1279CrossRefPubMed
12.
Sfiligoi C, de Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P, De Bortoli M (2003) Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 103:466–474CrossRefPubMed
13.
Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergun S (2000) The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res 20:5217–5220PubMed
14.
Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, Chung LP (2000) The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29:11–22CrossRefPubMed
15.
Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K (2004) Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 93:215–222CrossRefPubMed
16.
Szarvas T, Jäger T, Tötsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergün S, Rübben H (2008) Angiogenic switch of angiopietins-Tie2-system and its prognostic value in bladder cancer. Clin Cancer Res (in press)CrossRefPubMed
17.
Liersch R, Schliemann C, Bieker R, Hintelmann H, Buechner T, Berdel WE, Mesters RM (2008) Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia. Leuk Res 32:954–961CrossRefPubMed
18.
Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ, Hwang SC (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132:200–206CrossRefPubMed
19.
Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67:8429–8432CrossRefPubMed
20.
Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, Marmé D (2001) Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 4:123–131CrossRefPubMed
21.
Eble JN, Epstein JI, Sesterhenn I, World Health Organization classification of tumors (2004) Pathology and genetics of tumors of the urinary system and male genital organs. IARCC, Lyon, pp 89–158
22.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180CrossRefPubMed
23.
Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356–5362CrossRefPubMed
24.
Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL (2000) Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 82:161–166CrossRefPubMed
25.
O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL (1995) Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 55:510–513PubMed
26.
Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G, Glaser F, Kunze E (2004) Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24:2745–2756PubMed
27.
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergün S (2004) Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res 64:8932–8938CrossRefPubMed
28.
Beecken WD, Engl T, Hofmann J, Jonas D, Blaheta R (2005) Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder. J Cell Mol Med 9:655–661CrossRefPubMed
29.
30.
Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S (2005) Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 95:660–663CrossRefPubMed
31.
Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, Büchner T, Berdel WE, Mesters RM (2007) Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21:1901–1906CrossRefPubMed
32.
Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ, Hwang SC (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132:200–206CrossRefPubMed
33.
Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67:8429–8432CrossRefPubMed
34.
Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, Marmé D (2001) Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 4:123–131CrossRefPubMed
35.
Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D (2001) Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7:1992–1997PubMed
36.
Findley CM, Cudmore MJ, Ahmed A, Kontos CD (2007) VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 27:2619–2626CrossRefPubMed
37.
Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 100:2072–2078CrossRefPubMed
Metadata
Title
Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer
Authors
Tibor Szarvas
Tobias Jäger
Falk Droste
Markus Becker
Ilona Kovalszky
Imre Romics
Süleyman Ergün
Herbert Rübben
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2009
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9107-z

Other articles of this Issue 2/2009

Pathology & Oncology Research 2/2009 Go to the issue

Original Paper

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

Original Paper

MALT Type Lymphoma Demonstrating Prominent Plasma Cell Differentiation Resembling Fibrous Variant of Hashimoto’s Thyroiditis: a Three Case Report

Original Paper

Giant Cell Tumour and Central Giant Cell Reparative Granuloma of the Skull: do These Represent Ends of a Spectrum? A Case Report and Literature Review

Original Paper

Analysis of EGFR Gene Amplification, Protein Over-expression and Tyrosine Kinase Domain Mutation in Recurrent Glioblastoma

Original Paper

Adamantinoma of Long Bones: A Long-term Follow-up Study of 11 Cases

Original Paper

The Efficient Generation of Immunocompetent Dendritic Cells from Leukemic Blasts in Acute Myeloid Leukemia: A Local Experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits